Yttrium Y 90 Anti-CD19 Antibody BU-12 in Patients With Advanced Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Lymphocytic Leukemia

Inclusion Criteria:

Histologically confirmed CD19-positive (> 25% by flow cytometry evaluation of bone marrow blasts) disease of 1 of the following types:

Primary refractory or relapsed acute lymphoblastic leukemia (ALL) defined as persistent disease following a minimum of two different standard effective chemotherapy induction attempts at time of diagnosis or at relapse
Chronic Lymphocytic leukemia (CLL) following blast crisis (≥15% bone marrow blasts following a minimum of one standard effective chemotherapy induction attempt)
Human anti-mouse antibody (HAMA) must be negative
Patients who have relapsed ≥ 60 days following an autologous or allogeneic transplant are eligible if all other eligibility criteria are met
No active central nervous system (CNS) disease
ECOG performance status (PS) 0-2 or Karnofsky PS 60-100%
Life expectancy > 8 weeks
Total bilirubin ≤ 2.5 times upper limit of normal (ULN)
AST and ALT ≤ 2.5 times ULN
Creatinine normal OR creatinine clearance ≥ 60 mL/min
LVEF ≥ 45% by MUGA/ECHO
Oxygen saturation on room air > 92% and no oxygen requirement
Not pregnant or nursing
Negative pregnancy test
Fertile patients mus use effective contraception

Exclusion criteria:

History of allergic reactions attributed to compounds of similar chemical or biologic composition to of yttrium Y 90 anti-CD19 antibody BU-12 or other agents used in study

Uncontrolled illness including, but not limited to, any of the following:

Ongoing or active infection
Symptomatic congestive heart failure
Unstable angina pectoris
Cardiac arrhythmia
Psychiatric illness/social situations that would limit compliance with study requirements
HIV-positive
Active graft-vs-host disease
Less than 4 weeks since prior agents and recovered
Less than 7 days since prior therapy with any biologic agent, defined as a growth factor or cytokine
Less than 3 months since prior antibody or biologic anticancer therapy (e.g., alemtuzumab or epratuzumab)
Other concurrent investigational agents
Patients with peripheral blasts > 5,000/uL may receive concurrent hydroxyurea